First Tracks Biotherapeutics (TRAXV) Financials
TRAXV
NASDAQ
Key Financial Metrics
No financial data available for First Tracks Biotherapeutics, Inc..
Financial data is sourced from SEC filings. This company may not have filed yet or may trade on a non-US exchange.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | FY2025 | $12.0B | $4.0B | 32.9% | $137.5B | 78/100 |
| Regeneron Pharmaceuticals Inc REGN | FY2025 | $14.3B | $4.5B | 31.4% | $93.4B | 78/100 |
| Moderna, Inc. MRNA | FY2025 | $1.9B | -$2.8B | N/A | $96.4B | 31/100 |
| argenx SE ARGX | FY2025 | $4.2B | $1.3B | 30.4% | $56.3B | 62/100 |
| Revolution Medicines, Inc. RVMD | FY2025 | $0 | -$1.1B | N/A | $38.4B | — |